Last updated on February 2018

Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

---

Brief description of study

To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.

Detailed Study Description

To determine:

• Duration of response
• Progression free survival
• Proportion of responders 2 years after discontinuation of inecalcitol
• Duration of response after discontinuation of inecalcitol and imatinib
• Bone remodelling effect
• Safety of inecalcitol in combination with imatinib
• Quality of Life